CoChat

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S]

Open access
Ni, Yan G., Di Marco, Stefania, Condra, Jon H., Peterson, Laurence B., Wang, Weirong, Wang, Fubao, Pandit, Shilpa, Hammond, Holly A., Rosa, Ray, Cummings, Richard T., Wood, Dana D., Liu, Xiaomei, Bottomley, Matthew J., Shen, Xun, Cubbon, Rose M., Wang, Sheng-ping, Johns, Douglas G., Volpari, Cinzia, Hamuro, Lora, Chin, Jayne, Huang, Lingyi, Zhao, Jing Zhang, Vitelli, Salvatore, Haytko, Peter, Wisniewski, Douglas, Mitnaul, Lyndon J., Sparrow, Carl P., Hubbard, Brian, Carfí, Andrea, Sitlani, Ayesha · 2011 · Journal of Lipid Research
Cited by 134

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) regulates LDL cholesterol levels by inhibiting LDL receptor (LDLr)-mediated cellular LDL uptake. We have identified a fragment antigen-binding (Fab) 1D05 which binds PCSK9 with nanomolar affinity. The fully human antibody 1D05-IgG2 completely blocks the inhibitory effects of wild-type PCSK9 and two gain-of-function human PCSK9 mutants, S127R and D374Y. The crystal structure of 1D05-Fab bound to PCSK9 reveals that 1D05-Fab binds to an epitope on the PCSK9 catalytic domain which includes the entire LDLr EGF(A) binding site. Notably, the 1D05-Fab CDR-H3 and CDR-H2 loops structurally mimic the EGF(A) domain of LDLr. In a transgenic mouse model (CETP/LDLr-hemi), in which plasma lipid and PCSK9 profiles are comparable to those of humans, 1D05-IgG2 reduces plasma LDL cholesterol to 40% and raises hepatic LDLr protein levels approximately fivefold. Similarly, in healthy rhesus monkeys, 1D05-IgG2 effectively reduced LDL cholesterol 20%-50% for over 2 weeks, despite its relatively short terminal half-life (t(1/2) = 3.2 days). Importantly, the decrease in circulating LDL cholesterol corresponds closely to the reduction in free PCSK9 levels. Together these results clearly demonstrate that the LDL-lowering effect of the neutralizing anti-PCSK9 1D05-IgG2 antibody is mediated by reducing the amount of PCSK9 that can bind to the LDLr.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1194/jlr.m011445

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 134

Metadata

Authors
Ni, Y. G., Di Marco, S., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Hammond, H. A., Rosa, R., Cummings, R. T., Wood, D. D., Liu, X., Bottomley, M. J., Shen, X., Cubbon, R. M., Wang, S.-P., Johns, D. G., Volpari, C., Hamuro, L., Chin, J., Huang, L., Zhao, J. Z., Vitelli, S., Haytko, P., Wisniewski, D., Mitnaul, L. J., Sparrow, C. P., Hubbard, B., Carfí, A., & Sitlani, A.
Venue
Journal of Lipid Research
Publisher
Elsevier BV
Published
2011-01
Volume
52
Issue
1
Pages
78-86
ISSN
0022-2275 (ISSN-L)
OpenAlex
W2102467926
Cited by
134
References
10
FWCI
18.32
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.